{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Anti-VEGFANG2_Nanobody_BI_836880",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A nanobody directed against angiopoietin-2 (Ang2; ANGPT2)- and vascular endothelial growth factor (VEGF)-derived peptides, with potential antiangiogenic and antineoplastic activities. Anti-VEGF/ANG2 nanobody BI 836880 binds to Ang2 and VEGF and inhibits receptor binding; this prevents Ang2- and VEGF-mediated signaling and inhibits both tumor angiogenesis and tumor cell proliferation. Both VEGF and Ang2 are upregulated in a variety of cancer cell types and play a crucial role in angiogenesis. The nanobody is based on functional fragments of single-chain antibodies.",
    "fdaUniiCode": "IS7N1X9TSW",
    "identifier": "C126644",
    "preferredName": "Anti-VEGF/ANG2 Nanobody BI 836880",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C1742"
    ],
    "synonyms": [
      "Anti-VEGF/ANG2 BI 836880",
      "Anti-VEGF/ANG2 Nanobody BI 836880",
      "BI 836880",
      "BI-836880",
      "Bi-specific Anti-VEGF/Ang2 Nanobody BI 836880"
    ]
  }
}